ID
41942
Description
Study ID: 110921 Clinical Study ID: 110921 Study Title: A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00811733 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT00811733 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Ofatumumab Trade Name: N/A Study Indication: Waldenstrom Macroglobulinaemia The primary objective of this open-label, multi-center, Phase II study was to evaluate the safety and efficacy of Ofatumumab in subjects diagnosed with Waldenstrom Macroglobulinaemia. For the study, eligible subjects were enrolled to receive up to 3 cycles of treatment with Ofatumumab. The first cycle consisted of a single dose of 300 mg followed by 3 weekly doses of 1000 mg (Treatment Group A) or 4 weekly doses of 2000 mg (Treatment Group B) of Ofatumumab, with response assessment beginning at Week 12. Based on the Week 12-16 response, eligible subjects could receive up to 2 additional cycles of treatment. This form has to be filled out at the Screening Visit, the first and last weekly visits during the cycles of therapy, the cycle observation visits, unscheduled visits, withdrawal visits and the visits at the end of study/treatment.
Lien
https://clinicaltrials.gov/ct2/show/NCT00811733
Mots-clés
Versions (1)
- 19.02.21 19.02.21 -
Détendeur de droits
GlaxoSmithKline
Téléchargé le
19. Februar 2021
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
GSK Ofatumumab in Waldenstrom Macroglobulinaemia, NCT00811733
Physical Examination
- StudyEvent: ODM
Description
Physical Lymph Node Examination
Alias
- UMLS CUI-1
- C0031809
- UMLS CUI-2
- C0024204
Description
Please choose the location of the palpation, then answer the following questions
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0030247
- UMLS CUI [1,2]
- C0450429
Description
Please record palpable lymph nodes (> = 1.5cm)
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0024204
- UMLS CUI [1,2]
- C0522499
Description
Please specify the size of the largest palpable lymph node
Type de données
integer
Unités de mesure
- cm
Alias
- UMLS CUI [1,1]
- C0024204
- UMLS CUI [1,2]
- C0487742
Description
Please specify the size of the largest palpable lymph node
Type de données
integer
Unités de mesure
- cm
Alias
- UMLS CUI [1,1]
- C0024204
- UMLS CUI [1,2]
- C1444754
Description
If yes, please specify the size of the largest palpable lymph node
Type de données
integer
Unités de mesure
- cm2
Alias
- UMLS CUI [1,1]
- C0024204
- UMLS CUI [1,2]
- C0456389
Description
Physical Organ Exam
Alias
- UMLS CUI-1
- C0031809
- UMLS CUI-2
- C0178784
Description
Hepatomegaly
Type de données
boolean
Alias
- UMLS CUI [1]
- C0019209
Description
Liver size below costal margin
Type de données
integer
Unités de mesure
- cm
Alias
- UMLS CUI [1,1]
- C0456389
- UMLS CUI [1,2]
- C0023884
- UMLS CUI [1,3]
- C0542339
- UMLS CUI [1,4]
- C1288448
Description
Splenomegaly
Type de données
boolean
Alias
- UMLS CUI [1]
- C0038002
Description
Spleen size below costal margin
Type de données
integer
Unités de mesure
- cm
Alias
- UMLS CUI [1,1]
- C0037993
- UMLS CUI [1,2]
- C0456389
- UMLS CUI [1,3]
- C0542339
- UMLS CUI [1,4]
- C1288448
Similar models
Physical Examination
- StudyEvent: ODM
C2985720 (UMLS CUI [2])
C0024204 (UMLS CUI-2)
C0450429 (UMLS CUI [1,2])
C0522499 (UMLS CUI [1,2])
C0487742 (UMLS CUI [1,2])
C1444754 (UMLS CUI [1,2])
C0456389 (UMLS CUI [1,2])
C0023884 (UMLS CUI [1,2])
C0542339 (UMLS CUI [1,3])
C1288448 (UMLS CUI [1,4])
C0456389 (UMLS CUI [1,2])
C0542339 (UMLS CUI [1,3])
C1288448 (UMLS CUI [1,4])
Aucun commentaire